OIS at AAO 2015

Allegro Ophthalmics, LLC

Nov 12, 2015 10:45am ‐ Nov 12, 2015 10:53am


Allegro Ophthalmics is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of vitreoretinal diseases. Currently in multiple Phase 2 studies, Allegro’s Luminate has the potential to provide new treatment options for patients with diabetic macular edema, non-proliferative diabetic retinopathy, neovascular age-related macular degeneration and vitreomacular traction.


You must be logged in and own this session in order to post comments.